The case for medical marijuana in epilepsy

Epilepsia

Volumn 55, Issue 6, 2014, Pages 783-786

  Maa, Edward ^a,b   Figi, Paige ^c  

^a DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Dravet Syndrome Parent   (United States)

Author keywords

Cannabidiol; CBD; Charlotte's Web; Dravet syndrome; Medically refractory epilepsy; THC

Indexed keywords

MEDICAL CANNABIS; SODIUM CHANNEL NAV1.1;

ARTICLE; BENIGN CHILDHOOD EPILEPSY; CASE REPORT; CONVULSION; DAILY LIFE ACTIVITY; EPILEPTIC STATE; FEEDING APPARATUS; FEMALE; GENE MUTATION; HUMAN; INFANT; PRIORITY JOURNAL; SEVERE MYOCLONIC EPILEPSY IN INFANCY; TREATMENT OUTCOME; WEANING;

CANNABIDIOL; CBD; CHARLOTTE'S WEB; DRAVET SYNDROME; MEDICALLY REFRACTORY EPILEPSY; THC;

ANTICONVULSANTS; CANNABIDIOL; EPILEPSIES, MYOCLONIC; EPILEPSY; FEMALE; HUMANS; INFANT; MEDICAL MARIJUANA; TREATMENT OUTCOME;

EID: 84902352281     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12610     Document Type: Article

References (14)

1. Mechoulam R,. The pharmacohistory of Cannabis sativa. In, Mechoulam R, (Ed) Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press Inc, 1986: 1-19.
2. Consroe PF, Wood GC, Buchsbaum H,. Anticonvulsant nature of marihuana smoking. JAMA 1975; 234: 306-307.
3. Ellison JM, Gelwan E, Ogletree J,. Complex partial seizure symptoms affected by marijuana abuse. J Clin Psychol 1990; 51: 439-440.
4. Keeler MH, Reifler CB,. Grand mal convulsions subsequent to marijuana use. Case report. Dis Nerv Syst 1967; 28: 474-475.
5. Carlini EA, Leite JR, Tannhauser M, et al. Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 1973; 25: 664-665.
6. Wada JA, Wake A, Sato M, et al. Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats. Epilepsia 1975; 16: 503-510.
7. Wada JA, Osawa T, Corcoran ME,. Effects of tetrahydrocannabinols on kindled amygdaloid seizures and photogenic seizures in Senegalese baboons. Papio papio. Epilepsia 1975; 16: 439-448.
8. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to health volunteers and epileptic patients. Pharmacology 1980; 21: 175-185.
9. Elsohly MA, Slade D,. Chemical constituents of Marijuana: the complex mixture of natural cannabinoids. Life Sci 2005; 78: 539-548.
10. Lutz B,. On demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol 2004; 68: 1691-1698.
11. Russo EB, Burnett A, Hall B, et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005; 30: 1037-1043.
12. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-1101.
13. Russo EB,. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011; 163: 1344-1364.
14. Maa EH,. Use of Complementary and Alternative Medicine in an Urban County Hospital Epilepsy Clinic. Platform presentation. European Neurological Society Annual Meeting 2012.